Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Semmler

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
JHEP Reports : Innovation in Hepatology|January 6, 2026
<i>P</i> <i>NPLA3</i> and <i>TM6SF2</i> exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosisSophie Gensluckner, Helle Lindholm Schnefeld, Jan Embacher, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|August 7, 2025
UDFF and Auto pSWE accurately assess liver steatosis and fibrosis risk in obese patients with MASLDNina Dominik, Larissa Nixdorf, Michael Schwarz, et al.
Scientific Reports|July 30, 2024
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective studyLarissa Nixdorf, Lukas Hartl, Stefanie Ströhl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2026
Stage-specific drivers of clinical progression in advanced chronic liver diseaseBenedikt Simbrunner, Georg Semmler, Marta Bofill Roig, et al.
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Hepatology (Baltimore, Md.)|March 6, 2024
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertensionGeorg Semmler, Lukas Hartl, Yuly Paulin Mendoza, et al.
The Lancet. Gastroenterology & Hepatology|September 13, 2025
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort studyNikolaj Torp, Katrine Tholstrup Bech, Helle Lindholm Schnefeld, et al.
EMBO Reports|November 23, 2020
PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesisValentina C Sladky, Katja Knapp, Tamas G Szabo, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
JHEP Reports : Innovation in Hepatology|January 6, 2026
<i>P</i> <i>NPLA3</i> and <i>TM6SF2</i> exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosisSophie Gensluckner, Helle Lindholm Schnefeld, Jan Embacher, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|August 7, 2025
UDFF and Auto pSWE accurately assess liver steatosis and fibrosis risk in obese patients with MASLDNina Dominik, Larissa Nixdorf, Michael Schwarz, et al.
Scientific Reports|July 30, 2024
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective studyLarissa Nixdorf, Lukas Hartl, Stefanie Ströhl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2026
Stage-specific drivers of clinical progression in advanced chronic liver diseaseBenedikt Simbrunner, Georg Semmler, Marta Bofill Roig, et al.
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Hepatology (Baltimore, Md.)|March 6, 2024
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertensionGeorg Semmler, Lukas Hartl, Yuly Paulin Mendoza, et al.
The Lancet. Gastroenterology & Hepatology|September 13, 2025
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort studyNikolaj Torp, Katrine Tholstrup Bech, Helle Lindholm Schnefeld, et al.
EMBO Reports|November 23, 2020
PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesisValentina C Sladky, Katja Knapp, Tamas G Szabo, et al.
Pageof 20